San Francisco--Surgeon experience is an independent predictor of PSA progression in men undergoing radical prostatectomy, but among high-volume surgeons (those who performed more than 100 procedures) operating in a single institution, the individual surgeon alone is also a significant prognostic factor, according to a study by researchers at Memorial Sloan-Kettering Cancer Center, New York.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.